Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;77(3):403-410.
doi: 10.5173/ceju.2024.83. Epub 2024 Aug 18.

Baseline characteristics and clinical outcomes of prostate cancer patients on delayed palliative management: a PIONEER analysis based on big data

Affiliations

Baseline characteristics and clinical outcomes of prostate cancer patients on delayed palliative management: a PIONEER analysis based on big data

Lana Yh Lai et al. Cent European J Urol. 2024.

Abstract

Introduction: Delayed palliative management (DPM) is an alternative for prostate cancer (PCa) patients with poor performance status, or those who received radical treatment but progressed and no longer meet the criteria for curative treatment. PIONEER is a large network of federated data analytic platforms in PCa that aims to improve its care through the application of big data analytics. The objective of this study was to describe clinical baseline characteristics and outcomes of PCa patients receiving DPM using big data.

Material and methods: Descriptive study of patients on DPM from four databases in PIONEER (Pharmetrics Plus, Optum Clinformatics, Marketscan and Columbia University Irving Medical Center (CUIMC)). Baseline characteristics, including comorbidities (hypertension, type 2 diabetes (T2DM), asthma/chronic obstructive pulmonary disease (COPD) and obesity), were stratified by age. Outcomes of interest were annual emergency department (ED) visits, hospitalization and symptomatic progression. Additional outcomes were time to death, hospitalization and time to symptomatic progression for CUIMC.

Results: We included 13246 men with a median age of 68-75 and Charlson Comorbidity index of 6-8. The three most common comorbidities were hypertension (80-93% [>80 years] vs 69-80% [55-80 years] vs 59-64% [<55 years]), T2DM (29-41% [>80 years] vs 26-38% [55-80 years] vs 23-26% [<55 years] and asthma/COPD (28-37% [>80 years] vs 19-30% [55-80 years] vs 16-19% [<55 years]). ED visits and hospitalizations were highest in the first year of follow-up (19-33% and 21-48% respectively). The median time to death was 548 days (IQR 1265 days) and to symptomatic progression was 408 days (IQR 1125 days) in CUIMC.

Conclusions: Men on DPM were in their mid-seventies, with the three most common comorbidities being hypertension, T2DM and asthma/COPD, regardless of age groups. This study reflects the potential of PIONEER as a federated network of databases that may be used to harness big data in PCa research.

Keywords: common data model; data network; observational research; palliative management; prostate cancer; real world data.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prevalence of baseline comorbidities among prostate cancer patients on delayed palliative management, stratified by age group at diagnosis and database. US – United States; CUIMC – Columbia University Irving Medical Center
Figure 2
Figure 2
Frequency of outcomes during year 1 (0–365 days post index), year 2 (366–730 days post index) and year 3+ (731+ days post index) among prostate cancer patients on delayed palliative management stratified by database. US – United States; CUIMC – Columbia University Irving Medical Center
Figure 3
Figure 3
A) Kaplan-Meir plot showing death among prostate cancer patients on delayed palliative management in Columbia University Irving Medical Center (CUIMC). B) Kaplan-Meir plot showing hospitalization among prostate cancer patients on delayed palliative management in CUIMC. C) Kaplan-Meir plot showing symptomatic progression among prostate cancer patients on delayed palliative management in CUIMC.

References

    1. Culp MB, Soerjomataram I, Efstathiou JA, et al. . Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020; 77: 38–52. - PubMed
    1. IARC . WHO. Data visualization tools for exploring the global cancer burden in 2020. Access date December 2022.
    1. Mottet N, van den Bergh RCN, Briers E, et al. . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021; 79: 243–262. - PubMed
    1. Bruinsma SM, Zhang L, Roobol MJ, et al. . The Movember Foundation’s GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int. 2018; 121: 737–744. - PubMed
    1. Klotz L. Active surveillance in intermediate-risk prostate cancer. BJU Int. 2020; 125: 346–354. - PubMed

LinkOut - more resources